BioSpace News Archive

Nephron Pharma is rapidly expanding its presence in the area with a $12.5M investment to expand its manufacturing facility and create 125 new jobs.

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Gilead will pay an upfront payment of $175M, with additional milestone payments of up to $322M.

Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis.

INBRIJA is an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.

AVEO Oncology today announced clinical updates for two of its oncology programs: FOTIVDA (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway.

Veeva OpenData and Veeva CRM are part of Veeva Commercial Cloud, a suite of applications that Syner-Med is adopting to establish a foundation for their commercial operations as the company launches more new products over the next two years.

Curadev Pharma, India and UT Southwestern Medical Center in Dallas, USA announce a translational research partnership to identify small molecule drugs for the treatment of specific cancers.

The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.

Andy’s experience will be instrumental in achieving and leveraging anticipated milestones,.